[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359908-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359908-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bioinformatics-and-clinical-analysis-of-cetn2s-impact-on-platinum-resistance-and-prognosis-in-epithelial-ovarian-cancer","Bioinformatics and clinical analysis of CETN2’s impact on platinum resistance and prognosis in epithelial ovarian cancer","","Objective To investigate the role of centrin-2 (CETN2) in platinum resistance and its underlying mechanisms in ovarian cancer. Methods Pan-cancer analyses of CETN2 expression and associated genes used STRING and TIMER; GEO and TCGA supported survival, clinical correlation, and prognostic testing, alongside enrichment, co-expression, immune checkpoints, tumor microenvironment, and drug sensitivity. Clinical validation quantified CETN2 by qRT-PCR, assessed chemotherapy response, built logistic regression and decision-tree predictive models, and evaluated performance via ROC and Kaplan-Meier analysis. Results CETN2 mRNA and protein were elevated in cisplatin-resistant samples, associated with NER, oxidative phosphorylation, cell cycle pathways, negative immune checkpoint correlations, and immune infiltration patterns.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bioinformatics-and-clinical-analysis-of-cetn2s-impact-on-platinum-resistance-and-prognosis-in-epithelial-ovarian-cancer/359908/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bioinformatics-and-clinical-analysis-of-cetn2s-impact-on-platinum-resistance-and-prognosis-in-epithelial-ovarian-cancer/359908.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s primary objective?","Question",{"text":63,"@type":64},"To investigate CETN2’s role in platinum resistance and the mechanisms behind it in ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and tools were used to analyze CETN2?",{"text":68,"@type":64},"STRING and TIMER were used for gene-related analyses, while GEO and TCGA provided survival, clinical correlation, and prognostic data.",{"name":70,"@type":61,"acceptedAnswer":71},"How did CETN2 relate to chemotherapy response and prognosis?",{"text":72,"@type":64},"CETN2 showed predictive value for chemotherapy response, with higher expression in cisplatin-resistant and platinum-resistant cases, and prognostic associations assessed by Kaplan-Meier analysis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359908,1790183669,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Wei and Li Journal of Ovarian Research (2026) 19:174 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02028-7](https://doi.org/10.1186/s13048-026-02028-7)  \nRESEARCH Open Access  \nBioinformatics and clinical analysis of CETN2’s  impact on platinum resistance and prognosis in epithelial ovarian cancer  \nLin-yuan Wei1 and Li Li 1*  \nAbstract  \nObjective To investigate the role of centrin-2 (CETN2) in platinum resistance and its underlying mechanisms in ovarian cancer.  \nMethods We conducted a pan-cancer analysis of CETN2 expression and its associated genes using the STRING and TIMER databases. Data from the GEO and TCGA databases were employed for survival, clinical correlation, and prognostic analyses. Enrichment and co-expression analyses were performed to identify relevant pathways and genes. We also analyzed the tumor microenvironment, immune checkpoints, and drug sensitivity. For clinical validation, quantitative real-time PCR was used to measure CETN2 expression in patient samples and assess its correlation with chemotherapy response. Predictive models, including logistic regression and decision trees, were constructed. Their performance in predicting chemotherapy outcomes was evaluated using receiver operating characteristic (ROC) curves, and the prognostic impact of CETN2 was assessed via Kaplan-Meier survival analysis. Results CETN2 mRNA expression was significantly elevated in cisplatin-resistant samples. CETN2 was associated with the nucleotide excision repair (NER), oxidative phosphorylation, and cell cycle pathways and showed a negative correlation with several immune checkpoints. CETN2 expression demonstrated notable predictive value for chemotherapy response, particularly in platinum-sensitive ovarian cancer. It influenced stromal and immune-related scores in the tumor microenvironment, and differential expression levels correlated with significant variations insensitivity to specific drugs. In clinical samples, CETN2 expression was linked to immune infiltration patterns. Protein expression of CETN2 was significantly higher in platinum-resistant patients compared to platinum-sensitive patients and showed predictive utility for chemotherapy outcomes.  \nConclusion Upregulation of CETN2 may contribute to cisplatin resistance through pathways involving nucleotide excision repair, oxidative phosphorylation, and the cell cycle. CETN2 holds potential as a biomarker for platinumbased chemotherapy response and prognostic evaluation in ovarian cancer.  \nKeywords Ovarian cancer, Platinum drug resistance, CETN2, Prognosis  \n*Correspondence: Li Li [lili@gxmu.edu.cn](lili@gxmu.edu.cn)  \n1Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University, Ministry of Education, Nanning 530021, Guangxi, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nWei and Li Journal of Ovarian Resea","cbCaimwlxcFpuzaO","https://ap.wps.com/l/cbCaimwlxcFpuzaO","pdf",8386927,21,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n# Background\n## Rationale for platinum resistance research\n# Materials and methods\n## Online tool: PPI network construction\n## Enrichment analysis\n## Pan-cancer differential analysis\n## GEO data analysis","[{\"question\":\"What was the study’s primary objective?\",\"answer\":\"To investigate CETN2’s role in platinum resistance and the mechanisms behind it in ovarian cancer.\"},{\"question\":\"Which datasets and tools were used to analyze CETN2?\",\"answer\":\"STRING and TIMER were used for gene-related analyses, while GEO and TCGA provided survival, clinical correlation, and prognostic data.\"},{\"question\":\"How did CETN2 relate to chemotherapy response and prognosis?\",\"answer\":\"CETN2 showed predictive value for chemotherapy response, with higher expression in cisplatin-resistant and platinum-resistant cases, and prognostic associations assessed by Kaplan-Meier analysis.\"}]","Bioinformatics and clinical analysis of CETN2’s impact on platinum resistance and prognosis in epithelial ovarian cancer | PDF",1790138174,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/066429acd0813e2beb61d9749bcc8dab.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d9c2032c264f52984c740371d3ffb56.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6041a3c2bcd685f4ba3bb082c808bbf7.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2aca42a05718ce684de1f429bcb638f8.webp",980,1306]